The CLAAS® System by Conformal Medical emerges as a promising alternative to traditional stroke prevention techniques in atrial fibrillation patients, potentially reducing the risk of thrombosis without the use of oral anticoagulants.
In a recent advancement that promises to revolutionize the approach to stroke prevention in atrial fibrillation (Afib) patients, Conformal Medical, Inc. disclosed promising results for its CLAAS® System. Revealed at the prestigious Cardiovascular Research Technologies (CRT) 2024 conference, the novel left atrial appendage occlusion (LAAO) device displayed significant potential in reducing the risk of thrombosis, a common concern with existing treatments.
Afib, characterized by an irregular and often rapid heart rate, affects over six million individuals in the United States alone. Patients with this condition face a heightened risk of stroke, primarily due to the formation of blood clots in the left atrial appendage—a small, ear-shaped sac in the muscle wall of the left atrium. The conventional stroke prevention strategy involves the use of oral anticoagulants. However, these medications come with their own set of risks, including serious bleeding, which has driven interest towards alternative solutions like LAAO devices.
The CLAAS® System by Conformal Medical represents a significant innovation in this space. Unlike traditional devices, which rely on metal components and fabrics that may encourage clot formation, the CLAAS implant utilizes a unique combination of materials designed to minimize thrombogenic risk. The device comprises a foam cup supported by a nitinol skeleton, which is then covered by a fluoropolymer (ePTFE) layer. This design was compared to the Watchman FLX, a commonly used LAAO device, in an impressive study led by Dr. William Gray, a respected figure in the field of cardiovascular medicine.
During the CRT 2024 conference, Dr. Gray highlighted the outcome of an in vitro study which showcased the CLAAS device’s superior performance in terms of thrombogenicity, or its potential to form clots. The findings revealed that the CLAAS implant induced significantly less platelet deposition—a critical factor in clot formation—compared to the Watchman FLX. Specifically, there was a 44% reduction in platelet adherence to the CLAAS device, suggesting a lower likelihood of Device Related Thrombus (DRT), a serious complication associated with LAAO procedures.
These initial results not only bolster the potential of the CLAAS® System as a safer alternative for Afib patients but also underscore the importance of continuous innovation in the field of medical devices. However, as Dr. Gray cautiously noted, further research is needed to validate these findings in a clinical setting. Towards this end, Conformal Medical has initiated the CONFORM pivotal trial, a comprehensive study aiming to enroll roughly 1,600 patients to assess the safety and efficacy of the CLAAS® System compared to other LAAO devices available on the market.
The quest to improve stroke prevention in Afib patients is ongoing, with technological advancements like the CLAAS® System at the forefront of this effort. By potentially eliminating the need for long-term use of anticoagulants and their associated risks, such innovations hold the promise of a significant leap forward in patient care. As the medical community awaits the results of the CONFORM trial with bated breath, the future of stroke prevention in Afib patients looks increasingly hopeful, courtesy of breakthroughs like the CLAAS® System.